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Reverse transcription-polymerase chain reaction (RT-PCR) is a powerful tool for the detection and quantification of target mRNAs in basic research and routine clinical diagnosis. To assess the presence of amplifiable template RNA/cDNA, amplification of a control gene is used as an external standard. Commonly, housekeeping genes with minimal tissue-and developmental stage-specific variations are employed. 1, 2 In assays directed at the detection of tumor cell-specific fusion gene transcripts, a segment of one of the genes involved in the translocation is frequently used as a control. 3, 4 In most instances, a sequence from a single control gene is amplified to assess the availability of intact and amplifiable RNA. In view of the differences in stability of various mRNA species, 5 this approach may not provide a reliable control for integrity of the target sequence in all instances.
In a diagnostic setting, central referral laboratories receiving specimens from distant locations are often faced with the problem of partially degraded RNA samples, because the cell material may be exposed to ambient temperature for several days during transportation. In such samples, the use of a highly expressed control gene may yield a positive signal while the actual target transcript may no longer be detectable by the PCR assay. In patients with leukemia carrying a characteristic marker amenable to investigation by RT-PCR, which most commonly is a fusion gene transcript, one-step PCR is generally sufficient to permit its detection at the time of diagnosis. We, nevertheless, perform two-step nested PCR analysis of the target sequence as a means of confirming specificity of the amplified product, while the control gene is only submitted to one-step amplification. In largely degraded RNA preparations from diagnostic blood or bone marrow samples, a two-step amplification of the fusion transcript targeted is sometimes necessary to reveal its presence, while a one-step amplification of a moderately expressed control gene may be negative, and that of a highly expressed control gene positive. This scenario emphasizes the problem of different expression levels or discordant levels of stability between the target and the control gene transcripts. On the other hand, it indicates that the employment of a control gene expressed at a higher level may be useful in some instances, because it may indicate the presence of small amounts of amplifiable RNA/cDNA which could be sufficient to permit detection of the target sequence after two-step PCR amplification.
While in many diagnostic RT-PCR assays successful amplification of a specific target may be possible even in largely degraded RNA samples, investigation of the same targets for detection of minimal residual disease (MRD) requires RNA preparations of very good quality to achieve adequate sensi-tivity. Therefore, control gene analysis in RT-PCR assays for detection of residual tumor cells should help assess variations in RNA/cDNA quality to permit correct interpretation of the results. Integrity of the target sequence which is one of the essential factors influencing sensitivity of PCR tests, can only be assessed by indirect evidence provided, for example, by control gene amplification. The employment of a single control gene may not be an ideal approach to this task.
We have therefore established a multiplex PCR assay for co-amplification of sequences from four transcripts expressed at different levels. Selection of the control genes and the target sequences was based on extensive testing of more than 10 genes commonly used as controls in RT-PCR assays including aldolase, histone H3.3 (H3.3), beta-2-microglobulin (␤ 2 -MG), glucose 6-phosphate dehydrogenase (G6PDH), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ␤-actin, hypoxanthine phosphoribosyltransferase (HPRT), porphobilinogen deaminase (PBGD), dihydrofolate reductase (DHFR), Abelson (ABL) and BCR.
Genes known to have processed pseudogenes (aldolase,   6 H3.3, 7 G3PDH, 8 ␤-actin 9 (M55014), HPRT (U10112) and DHFR 10 ) were excluded to avoid the risk of false positive results in case of contamination with genomic DNA. 5, 11 Primers located in different exons were designed to facilitate the discrimination of PCR products derived from gDNA and cDNA. Concentrations of PCR components and cycling parameters were optimized for each of these genes, and finally, primers suitable for multiplex PCR were selected on the basis of compatible reaction conditions and product sizes. Based on these selection criteria, we established a multiplex PCR assay permitting co-amplification of mRNA segments derived from four different genes including BCR, ABL, ␤ 2 -MG and PBGD. The former two are expressed at moderate levels, whereas the latter two show relatively high levels of expression in most cell types. Co-amplification of the four target sequences selected yields PCR products ranging from 128 to 377 bp. The minimum difference in length between individual products of 65-94 bp permits easy evaluation upon agarose gel electrophoresis. Primer sequences, genomic location and predicted size of amplified cDNA and gDNA fragments are indicated in Table 1 .
Contemporaneous amplification of differentially expressed control genes by the multiplex PCR assay permits assessment of the extent of RNA degradation. The reliability of this method was evaluated by screening of more than 100 tumor specimens that had been previously studied for the expression of ABL and ␤ 2 -MG mRNAs by conventional RT-PCR analysis. In all samples displaying a strong amplification signal of the moderately expressed ABL gene in single-target PCR analyses, all four control gene fragments were amplified in the multiplex assay, indicating adequate mRNA/cDNA quality. RNA/cDNA preparations of suboptimal quality were characterized by loss of the BCR signal, while further deterioration of sample quality resulted in an additional loss of either the ABL or the ␤ 2 -MG signal. In single-target PCR assays, such samples were negative for ABL, but positive for the highly expressed ␤ 2 -MG gene. In samples of very poor mRNA/cDNA quality displaying a weak ␤ 2 -MG signal in the single-target PCR assay, the multiplex amplification revealed a PBGD signal only. The inability to amplify a ␤ 2 -MG fragment in a sample by singletarget PCR corresponded to complete lack of signals in the multiplex assay. Examples of multiplex PCR amplification of good, intermediate, and poor RNA/cDNA quality preparations are shown in Figure 1 . The discrepancy between single-target and multiplex PCR regarding the presence or absence of the ␤ 2 -MG signal might be attributable to competition for avail-
Figure 1
Quality assessment of RNA/cDNA preparations by multiplex PCR. Transcript segments of four genes (BCR, ABL, ␤ 2 -MG and PBGD) were co-amplified by one-step PCR. In samples with high quality RNA/cDNA (lanes 2-4), all four fragments were successfully amplified. Loss of the BCR signal (lanes 5, 6) indicated suboptimal quality, and additional loss of the ␤ 2 -MG signal (lane 8) or the ABL signal (lane 9) was indicative of relatively poor RNA/cDNA quality. Very poor quality templates yielded a PBGD signal only (lane 10). In this multiplex assay, PBGD has been the most stable target, present in over 99% of the samples investigated. In a series of over 100 specimens with amplifiable cDNA tested, the only sample lacking the PBGD-derived band exhibited ␤ 2 -MG and ABL signals (lane 7). Lanes 1 and 12: molecular size marker (100 bp ladder; GIBCO/BRL, Gaithersburg, MD, USA); lane 11: negative control. PCR was carried out in a Perkin-Elmer Cetus DNA thermal cycler (model 2400). Individual reactions contained 10 mM Tris (pH 8.3), 50 mM) KCl, 2.5 mM MgCl 2 , 150 M of each of the deoxynucleotide triphosphates, 0.5 units of AmpliTaq Gold (all reagents were from Perkin Elmer, Norwalk, CT, USA), approximately 50 ng template, 5.4 pmol of the BCR and ␤ 2 -MG primers, 4.8 pmol of the ABL primers, and 4.3 pmol of the PBGD primers in a total volume of 30 l. Reactions were initiated by heating the samples at 95°C for 8 min. Subsequently, 35 cycles were performed with denaturation at 96°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 40 s. A final extension step for 7 min at 72°C was included. Fifteen microliters of the PCR product were electrophoresed on 2% agarose gels and visualized with ethidium bromide. It is important to note that the use of other reagents or another thermal cycler will likely require new optimization of the protocol.
able substrates between ␤ 2 -MG and other primers in the multiplex assay. This notion is supported by the observation that samples negative for ␤ 2 -MG, and positive for PBGD in the multiplex PCR, generally show successful ␤ 2 -MG amplification when tested with the same reagents and under the same cycling conditions in a conventional single-target PCR assay.
The primer combinations used in the multiplex PCR reaction were tested for their ability to amplify genomic DNA fragments of the respective genes. To address this question, all
Figure 2
Amplification of genomic DNA fragments in single-target PCR, and multiplex PCR of cDNA samples with gDNA contaminants. Each of the four primer pairs was tested in single-target PCR assays containing gDNA as template. The reaction conditions and cycling parameters of the single-target PCR were as indicated in Figure 1 , the only modification being an adaptation of the primer concentrations to 10 pmol. With BCR primers (lane 2) and ␤ 2 -MG primers (lane 3) which span large introns, no genomic DNA product was amplifiable, but with ABL primers (lane 4) and PBGD primers (lane 5), genomic fragments of the expected size could be amplified. To test the effect of contaminating gDNA on the multiplex PCR assay, RNA/cDNA templates derived from cell lines were mixed with different amounts of gDNA. In samples containing a cDNA/gDNA ratio of 1:1 (lane 8), the ABL gene-derived DNA fragment of 0.8 kb was detected in addition to the c-DNA-derived amplification products. At a cDNA/gDNA ratio of 9:1, the ABL-derived band was still visible (lane 7). Lane 9 shows multiplex PCR amplification of a clinical sample containing an unknown amount of contaminating gDNA. As shown in lanes 7-9, the presence of contaminating gDNA compromises the efficiency of cDNA target amplification. Multiplex PCR analysis of the above RNA/cDNA samples derived from cell lines revealed products of all four cDNA targets when no gDNA was admixed (not shown). Lanes 1, 6 and 10: molecular size marker (100 bp ladder, GIBCO/BRL).
primer pairs were tested in single-target PCR reactions using pure gDNA as template. Due to the relatively small introns spanned by the primers for ABL and PBGD, specific PCR products of about 0.9 and 0.8 kb were obtained (Table 1) , while no amplification products of BCR and ␤ 2 -MG were seen under the assay conditions employed. To test the effect of gDNA contamination of RNA preparations on the multiplex PCR assay, cDNA samples were mixed with gDNA at various proportions. Under these artificial assay conditions, contaminating gDNA down to a 10% level was sufficient to produce a 0.8 kb amplification signal of the ABL gene. In contrast to the results of single-target PCR assays, no gDNA signal of the PBGD gene was amplified under the multiplex PCR conditions. The results of amplification using different cDNA/gDNA mixtures in the multiplex PCR assay are shown in Figure 2 .
The multiplex PCR assay presented cannot supplant other approaches to assessment of RNA integrity, such as evaluation of ribosomal RNA bands on (non)-denaturing agarose gels. However, in comparison to single-target control PCR tests, this assay provides a more comprehensive control of different mRNA species in the sample analyzed, which may yield relevant information on the integrity of the target sequence. The ability to assess gradual differences in the quality of RNA/cDNA preparations provides an additional tool for determining the expected sensitivity of RT-PCR assays.
COMMENTARIES Commentary from A El-Osta
Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne 3002, Victoria, Australia I would like to respond to the issues raised by Dr Kidd regarding appropriate controls used in reverse transcriptase-polymerase chain reaction (RT-PCR). These questions are significant and pertinent to investigators using RT-PCR, in either a qualitative or quantitative approach and certainly underlie some of the challenges faced by those interpreting RT-PCR results. I believe there are several important points regarding performance and reliability of amplification that warrant discussion.
In the past, the debate regarding ␤-actin as a control gene in RT-PCR has led to some discussion concerning its suitability as an endogenous mRNA reference. 1 Other than the functional form of the ␤-actin gene, there are processed intronlacking pseudogenes that exist with equal sequence length to the endogenous mRNA. Therefore, the problem of generating a false positive result in the RT-PCR by gDNA interference is important and requires closer examination.
Low levels of gDNA do persist 2, 3 and ultimately confound the RT-PCR result irrespective of the RNA extraction method selected. As little as 0.1% contamination can interfere with RT-PCR to generate a false positive signal. 4 Menon et al 5 observed gDNA contamination in RNA preparations, by demonstrating the presence of processed ␤-actin pseudogenes. Interestingly, Garbay et al 6 observed interference by processed glyceraldehyde phosphate dehydrogenase (GAPDH) and ␤-actin pseudogenes in their RNA preparations, irrespective of the type of RNA method selected. Subsequent DNase treatment was unable to remove the contaminating gDNA. In considering this type of evidence and the criticism of ␤-actin, Soutar et al 7 evaluated ␤-actin and GAPDH suitability as internal controls in RT-PCR. GAPDH expression was three times higher than that of ␤-actin, yet what is more important, the levels within the two groups remained comparable, while PCR on non-reverse-transcribed RNA did not display any DNA contamination.
Dirnhofer et al 4 described a thorough method for the removal of contaminating gDNA using RNase-free-DNase treatment of RNA before reverse transcription with great success. Due to the conflicting observations it is difficult to come to any firm conclusion regarding the capacity of ␤-actin as a housekeeping gene. To prevent any misinterpretation with gDNA contamination in the RT-PCR, tests should be performed to confirm either the absence or presence of gDNA in the RT-PCR. These studies reinforce the opinion that thorough testing on non-reverse-transcribed RNA is essential to exclude the possibility of homologous gene amplification.
I have used histone 3.3 as an endogenous reference in RT-PCR and in relative quantitation of low level mRNA in B-lymphocytes. 8 The primers were designed to span an intron sequence to eliminate gDNA contamination. 9 The human histone 3.3 variant is a ubiquitously expressed cell cycle-independent gene that is constitutively displayed. 10 I have found H3.3 to be comparably expressed between B-CLL patients and T cell leukemia cell lines with little irregularity.
Secondly, I do not believe there is a universal control that should be used as a reference for mRNA integrity, instead judicious selection of the mRNA reference for the specific application is fundamental. ␤ 2 -microglobulin 11 (␤ 2 -m), GAPDH 12 , and ribosomal RNA 13 have all been used in the past as housekeeping genes. As pointed out by Dr Lion, 14 the stability of different RNA species varies making the selection of a control difficult. One of the most common methods for evaluating RNA integrity is ethidium bromide staining of rRNA. An evaluation of gene expression in patients with lymphoma, showed that 28s rRNA was most consistently stained with ethidium bromide when compared between different patients and cell lines. 15 Of the three control genes analyzed, ␤ 2 -m was most consistent whereas GAPDH and ␤-actin were found to be displayed with the greatest level of variation. This is notable, as previous studies have shown that the reliability of ␤ 2 -m as a control can be confounded since serum levels are unstable in lymphoma. 16, 17 There is further evidence that the ␤-actin gene is unstable and expression levels alter following cell tumorigenesis. 18, 19 It was demonstrated that the ␤-actin mRNA level increased following treatment with tumor differentiating agents in mouse carcinoma relative to normal mouse epidermis. 20 Therefore, careful consideration must be given when selecting an endogenous mRNA control to identify its stability for RT-PCR.
It would be difficult to select a control that was expressed in a constitutive manner or one that did not perform differently due to transcriptional regulation. Genes that do not fluctuate in this manner are probably the exception rather than the norm and rigorous testing of the control gene would prove indispensable. It is significant that commercial RT-PCR kits provide primers for ␤-actin along with a variety of other housekeeping genes 21 suggesting that the stringent comparison and prudent selection of the reference gene ultimately rest on the user to choose the appropriate mRNA control.
The issues considered in this debate will not completely resolve the primary dilemma of processed ␤-actin pseudogenes in RT-PCR. These discussions do reveal the thoughtful approach taken by investigators in the use of ␤-actin. I believe from recent literature that all RNA preparations should be treated for gDNA contamination particularly if there is a history of gDNA amplification. However, can we assume that treatment will not adversely influence RT-PCR yield? It may prove valuable to use other housekeeping genes with primers designed to span an intron. The latter suggestion is probably inevitable since treatment for gDNA is an additional step requiring inactivation and purification prior to cDNA conversion. Despite the control chosen, concerns over gene stability still persist and clearly thorough evaluation of any endogen-ous mRNA reference is essential to ensure interference-free results in interpreting RT-PCR.
Commentary from H Karlic, M Radolf and M Pfeilstö cker
L Boltzmann Institute for Leukemia Research and Hematology and 3rd Medical Department Hanusch Hospital, H Collinstrasse 30, A-1140 Vienna, Austria
We read with interest the Debate round-table 1,2 discussing the risk of obtaining false information on transcriptional activity by amplifying ␤-actin as a positive control in RT-PCR. Arguments were based on the fact that the human genome contains at least 19 processed ␤-actin pseudogenes which are derived from cellular mRNAs and as such lack introns. 3 However, it might not be justified to deem all publications using actin as positive control for RT-PCR as inappropriate. It is a generally accepted practice in RT-PCR that controls involving genomic DNA of the same source from which mRNA was extracted should be used for any primer pair. Figure 1 gives an example of such an assay which should be part of any RT-PCR application, irrespective of research or routine. Another argument relates to the fact that numerous primer combinations may be selected from the 2554 bp long actin gene. 4 More than 7 years of experience in our laboratory indicate that primer combinations exist for ␤-actin which may have a much lower risk of cross-reacting with genomic DNA than the example mentioned by Taylor and Heasman 5 who describe a combination of primers from actin exons 3 and 4. Our experience indicates that the primers derived from several positions between nucleotides 427 and 1908 corresponding to actin exons 4 and 5 are relatively cDNA specific (Figure 1 , lane 1), at least under general stringent PCR conditions (annealing temperature 55°C or higher). However, even under these conditions, we found that the risk of detecting crossreaction with pseudogenes is about 1/100 cases. This underlines that detection of pseudogenes does not just depend on the various PCR conditions but also on the individual genotypes of the investigated samples. A combination of primers for ␤ actin which were claimed to be highly cDNA specific 6 but have only been tested in a small number of individuals should therefore be critically re-evaluated.
Besides the use of actin primers as an indirect marker for RNA integrity, amplicons obtained with these primers which are commercially obtainable from Clontech (Palo Alto, CA, USA) have also been used successfully as probes to verify equal loading of RNA on Northern blots (for example see Ref. 7). As it is well known that pseudogene-associated false positive or false negative results may also be obtained with other reference genes, a careful selection of the appropriate control is a general prerequisite for any routine or scientific application of RT-PCR.
Another typical property of ␤-actin is its high expression in many cell lineages. In a study which focused on the analysis of the hematopoiesis-associated G-protein ␣ subunit G␣16, 8 it could be shown that in some hematopoietic lineages, the G␣16-specific signal may be even stronger than the actin-
Figure 3
Agarose gel elecrophoresis and visualization by ethidium bromide staining of PCR products generated from genomic DNA (upper panel) and cDNA (lower panel) templates which were both isolated from the same source (human peripheral blood from a patient with a myelodysplastic syndrome). PCR conditions were the same for all assays (1 min 95°C/1 min 55°C/1 min 72°C, 45 cycles). A 100 bp ladder (Pharmacia) was used as a size marker (SM). For negative controls (lanes: 5 = actin, 6 = ␤-globin, 7 = G␣16 and 8 = cABL), distilled water was used instead of DNA or cDNA templates. Signals below 100 bp represent primer polymerisation products (indicated by asterisks), in contrast to specific signals which are indicated by arrows. As shown, amplification of a 300 bp actin sequence (lane 1) could only be achieved with cDNA, but not with genomic DNA; a signal with an intron-derived ␤-globin-specific primer combination (110 bp) (lane 2) could only be achieved with genomic DNA; primers for the hematopoiesis-specific G-Protein G␣16 detected the 257 bp cDNA-specific fragment (lane 3), and the ABL primers (2) amplified a 600 bp fragment from genomic DNA, and the cDNA-specific 183 bp fragment which appeared in addition to a 600 bp signal in the RT-PCR assay displayed (lane 4). Primers sequences: ␤-actin sense: 5′-gAAACTACCTTCAACTCCATC-3′; ␤-actin antisense: 5′-CTAgAAgCATTTgCggTggACgATggAggggCC-3Ј; ␤-globin sense 5′-ACACAACTgTgTTCACTAgC-3′; ␤-globin antisense 5′-CAACTTCATCCACgTTCACC; G␣16 sense: 5′-TACTCggAggAggACTgCAAg-3′; G␣16 antisense: 5′-ATCgAgCAggTggAATTCCCg-3′; ABL sense: 5′-AgCATCTgACTTTgAg-3′; ABL antisense: 5′TTATAgCCTAAgACCCgg-3′. specific signal. As an alternative to actin, other genes such as GAPDH (glycerine aldehyde phosphate dehydrogenase) would be a good control for RT-PCR, but should be handled with care in view of the fact that the level of GAPDH expression is influenced by many regulatory genes such as growth factors and other cytokines, tumor-promoting phorbol esters and lipopolysaccharides.
Moreover, application of actin as a positive control may lead to wrong interpretation of RT-PCR assays, if the gene investigated is expressed at a markedly lower level. Thus, the application of actin may be limited due to its overexpression. We agree with the majority of groups that the best reference gene for the BCR/ABL transcript is the normal c-ABL in chronic myeloid leukemia (CML) as well as in BCR/ABL-positive acute lymphoid leukemia (ALL). As the latter example refers to a disease with a well defined chromosomal marker, other techniques such as cytogenetics and FISH (fluorescence in situ hybridization) are highly recommendable as additional controls.
In conclusion, this Debate round-table reminds us that the reliability of some RT-PCR controls is limited by the fact that human individuals harbor a lot of highly variable pseudogenes which may be amplified at appropriate conditions, thus leading to false positivity of control gene amplifications.
Commentary from F Lo Coco and D Diverio
Dipartimento di Biotecnologie Cellulari ed Ematologia, Università 'La Sapienza', Via Benevento 6, 00161 Roma, Italy
We are grateful to the Editor of Leukemia and to Prof T Lion for inviting us to participate in this timely and interesting debate on appropriate controls for RT-PCR analyses. We will comment on some specific issues concerning the amplification of the PML/RAR␣ hybrid in acute promyelocytic leukemia (APL).
Due to a number of reasons, detection of this fusion gene for either diagnostic or monitoring purposes is extremely relevant in clinical practice and certainly more cogent for patient management than is identifying chimeric genes in other leukemic subsets. In fact (1) its detection correlates with response to a specific treatment approach and the corresponding karyotypic abnormality (ie the t15;17) is frequently not identifiable due to technical difficulties; (2) in light of the associated lifethreatening coagulopathy, the disease is to be considered a hematologic emergency, requiring immediate recognition and, again, specific therapy; (3) persistence or reappearance of minimal residual disease (MRD) as detected by RT-PCR of PML/RAR␣ after consolidation therapy correlates in almost all reported studies with impending hematologic relapse. 1 In our own experience of more than 150 patients enrolled in a single protocol and prospectively evaluated by PCR, this correlation has led to amending the ongoing GIMEMA trial 'AIDA' by anticipating salvage therapy in patients who convert to PCRpositive during follow-up. 2 Based on such relevance for therapeutic decision, and in light of some aspects quite peculiar to the disease and to its specific genetic abnormality, a tailored commentary on RT-PCR amplification of PML/RAR␣ is overdue. Besides discussing the appropriate controls for the reaction, we would like to mention the various factors related to the disease biology which affect the sensitivity of the assay. Also, we think it is appropriate to tackle separately the technical problems linked to diagnostic and monitoring tests.
At presentation, RNA yield is usually poorer in APL than in other leukemias. With the exception of the infrequent microgranular variant, the disease is typically leukopenic. Probably because of the associated coagulopathy, which may lead to rapid clotting of samples and enzyme release, RNA degradation is frequent. In our multicenter trial, in which diagnostic PML/RAR␣ determination is a mandatory prerequisite for patient eligibility, we have considerably improved the rate of successful RNA extraction (centrally performed by referral laboratories) after recommending to peripheral Institutions the o.n. shipment of locally prepared mononuclear cells diluted in a guanidium isothiocyanate (GTC) solution. 2, 3 By contrast, in other leukemic subsets good quality RNA is equally obtainable from whole blood or bone marrow specimens sent by o.n. courier. These considerations might be of interest for the colleagues involved in (or who are setting up) molecular studies in the context of large multicenter trials. After extraction, it is highly recommended to carefully evaluate RNA quality by running a formaldehyde minigel to visualize ribosomal bands. Such a procedure, to be performed in remission samples as well, also permits detection of gross DNA contamination. There is no doubt that CsC1-ultracentrifuge RNA preparation is preferable with respect to the more commonly used guanidium thiocyanate-acid phenol method, 4 particularly in terms of RNA purity, but the former is more laborious and time consuming, and its application in laboratories processing a high number of samples is quite problematic.
Positive controls of the hybrid gene in the diagnostic reaction are usually performed using RNA aliquots from the NB4 cell line, which contains the long isoform or bcr1-2 transcript type only. Such controls should also include an RNA with the short transcript (or bcr3) type. By using either external and internal primers on the PML side for diagnostic identification of the hybrid gene and of breakpoint type, there is a chance of performing a sort of double check, because a bcr3 transcript would only be detectable with the external PML primer (the internal resulting in no amplification) whereas a bcr1-2 case would be amplifiable with either set being visible as a multiple band pattern (due to alternative splicing of downstream PML exons) using the external, and as a single band using the internal PML primer. This approach is also of some aid in the identification of non-specific PCR products, although the occurrence of this latter is better ruled out following hybridization with a specific probe. Negative controls aimed at ruling out false positivity due to contamination should include at least two vials, ie an all-reagents and no-template tube (water control) and a no-RT tube to verify RNA or cDNA contamination. To further assess RNA integrity and to verify the efficiency of the RT step, we have long since abandoned the amplification of ␤-actin, as recommended by several colleagues in this Debate round-table. 5, 6 We agree that amplifying one of the fusion partners is a good option for diagnostic analyses, provided that primers encompass the translocation breakpoint, so that a similar template copy number of translocated vs normal allele would be made available in the reaction. Indeed, we use RAR␣ as a control gene either in diagnostic or in remission experiments.
2,3 However, we would like to take this opportunity to raise the issue of whether appropriate controls for RT, in any fusion gene assay, should necessarily be identical in diagnostic and in MRD tests. Is it not the case of distinguishing diagnostic from MRD issues and, therefore, to adapt ad hoc controls to such distinct biological and experimental situations?
Issues related to remission (or MRD) studies may, in fact, be more or less relevant in the diagnostic context, and vice versa. The choice of one of the two partners for the RT control (RAR␣ or PML in our case) might be less satisfactory in the MRD setting, as suggested by van der Reijden and Jansen. 7 In fact, it is well established that the hybrid PML/RAR␣ is poorly expressed and more unstable than the wild-type counterparts, 8 and false negative cases (evolving in early relapse after a PCRnegative result) have been frequently reported in APL monitoring studies. [1] [2] [3] Nonetheless, it may be argued that the control gene for RT, whichever translocation is considered, will always result more stable and easier to amplify than the hybrid one. Thus, one possible alternative option is to dilute by 1-2 logs the control RNA, as indicated by Macintyre and Gabert, 9 which would allow better appreciation of the sensitivity of MRD tests. Also, we believe that for remission assays, there is no need to choose one of the two translocation partners. Porphobilinogen decarboxylase (PBGD) or other ubiquitously low-expressed genes devoid of known pseudogenes should work fine as well, and might be used as 10 −1 or 10 −2 dilutions. As a positive control for the PML/RAR␣ hybrid in remission studies (ie to verify the translocation primer set and amplification efficiency), it is important to use an RNA with the same breakpoint type as the one contained in the examined sample. This avoids the resolution of a multiple band pattern which would indirectly result in a less sensitive assay. For these reasons, we prefer not to deal with MRD samples of patients with no diagnostic molecular characterization (ie having evidence of the translocation at the karyotypic level only). Here again dilution of the positve control is recommendable.
Finally, despite all the above discussed experimental precautions to rule out false positivity due to contamination, we reasoned that confirmation of results in a second patient sample is appropriate for cases converting to PCR positive. Particularly if a therapeutic intervention is to be based on MRD results, this is the best way to exclude sample contamination. Thus, treatment of molecular relapse is undertaken in our trial after confirmation of PCR-positive conversion in two successive BM specimens. 2 equal to that of the gene of interest. This is important for accurately assessing the level of amplifiable RNA present in a given sample. This is particularly important, especially in the context of a multi-centre study, when samples are received by post from a number of centres, or when the quantitation is carried out in different centres.
We have tested the suitability of AML1 and ABL genes as controls for the quantitative RT-PCR amplification of AML1-MTG8 and PML-RARA. The level of the AML1 gene was found to vary between samples at different phases of leukemia with t(8;21), unlike ABL which was not affected by both t(8;21) and t (15;17) . The degradation rate of ABL was then compared with those for AML1-MTG8 and PML-RARA. In both cases samples were left at room temperature for 0, 24 and 48 h and the level of ABL and the relevant fusion gene transcripts (AML1-MTG8 and PML-RARA) was assessed. 4 Our data show that the level of degradation of ABL transcripts (1 log over 48 h) is equivalent to that for AML1-MTG8 and PML-RARA. These data show that ABL is a suitable control gene for quantitation of AML1-MTG8 and PML-RARA.
Commentary from L Vieira and MG Boavida
Departamento de Genética Humana, Instituto Nacional de Saú de Dr Ricardo Jorge, Av Padre Cruz, 1699 Lisboa Codex, Portugal
We believe that the ongoing Debate round-table on appropriate controls for reverse transcription-polymerase chain reaction (RT-PCR) assays 1,2 is worth intense discussion, considering the generalized use of this methodology in the diagnosis of hematological malignancies. Reliable RT-PCR results are mainly dependent on the quantity and quality of RNA preparations, which may be assessed by analysis of control genes chosen according to specific criteria.
In spite of the technique used for preparing poly(A) + or total RNA, RNA samples may often be contaminated with genomic DNA. If this contamination interferes with the correct interpretation of RT-PCR results, it is most advantageous to check for its presence in RT-PCR reactions. Primers should be designed to encompass a small, amplifiable intron (less than 1 kb), the product of which is distinguishable in size from the cDNA sequence. In this context, we have been performing a single-step amplification of a segment spanning exons a2 to a3 of the ABL gene, 3 which is particularly appropriate for detecting the presence of genomic DNA in RNA preparations since these exons are separated by a 0.6 kb intron. This also allows for assessment of the integrity of the RNA in the same reaction.
Considering the discussion on ␤-actin adequacy as a control gene in RT-PCR experiments, it is our belief that it cannot be considered a reliable indicator for that purpose. ␤-actin has multiple processed pseudogenes which lead to identical size fragments when amplified either from cDNA or genomic DNA. On the other hand, it is expressed at a much higher level than most other genes, namely the BCR-ABL fusion gene. 4 Among the samples we have analyzed for expression of the ABL gene in RT-PCR reactions, two showed only genomic DNA amplification. Amplification of RAR␣ gene transcripts in both samples using nested primers 5 revealed only a very faint band, confirming the low levels of cDNA present. When the samples were amplified with ␤-actin primers, 6 bands of high intensity were observed after a single round of amplification. Thus, in the presence of an insufficient or partially degraded RNA sample, amplification of ␤-actin can lead to wrong interpretation of RT-PCR results. By the same token, ␤-actin cannot be regarded as an adequate control gene for analysis of the quantitative expression of specific genes in RT-PCR reactions.
Preliminary conclusions from two rounds of commentaries and articles
(1) ␤-Actin should no longer be regarded as an appropriate control gene for RT-PCR assays owing to its very high level of expression, and the presence of processed pseudogenes in the human genome. ␤-Actin primer combinations claimed to be cDNA specific apparently may result in amplification of similar-sized products from gDNA templates under certain experimental conditions or in certain individuals. (2) Suitable control genes should have no highly related homologues and/or pseudogenes in the human genome, and should be ubiquitously expressed at a level which does not exceed the expression level of the gene being investigated. ( 3) The selection of primers for PCR analysis of an appropriate control gene should either prevent amplification of template DNA or permit distinction between PCR products resulting from DNA and RNA template, eg by amplification across an intron sequence. (4) For a number of RT-PCR applications it is helpful to assess the overall quality of RNA preparations by evaluating ribosomal RNA bands after gel electrophoresis. (5) PCR amplification of transcripts from several control genes, eg by multiplex PCR, may permit a more comprehensive assessment of template quality. (6) The selection of control genes for quantitative PCR assays requires additional considerations regarding the degradation rate of the control gene vs the gene tested, and the possible effect of the disease investigated on the expression level of the control gene.
